Tolvaptan News and Research

RSS
Tolvaptan is a vasopressin V2 receptor blocker that shows promise for management of heart failure.
Cancer drug holds promise for shrinking polycystic kidney cysts

Cancer drug holds promise for shrinking polycystic kidney cysts

Melatonin reduces cysts in the renal tubules of fruit flies

Melatonin reduces cysts in the renal tubules of fruit flies

Promising new drug being developed for polycystic kidney disease

Promising new drug being developed for polycystic kidney disease

Scientists develop new class of drugs to treat hereditary kidney disease

Scientists develop new class of drugs to treat hereditary kidney disease

Otsuka’s JINARC approved for treatment of patients with CKD stage 4 ADPKD

Otsuka’s JINARC approved for treatment of patients with CKD stage 4 ADPKD

Research reveals long-term efficacy of drug used to treat common cause of kidney failure

Research reveals long-term efficacy of drug used to treat common cause of kidney failure

Mild reduction in food intake slows development of autosomal-dominant polycystic kidney disease

Mild reduction in food intake slows development of autosomal-dominant polycystic kidney disease

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

First European approval of drug to treat genetic kidney disease ADPKD

First European approval of drug to treat genetic kidney disease ADPKD

EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

Discovery reveals promising target for treatment of end-stage heart failure

Discovery reveals promising target for treatment of end-stage heart failure

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Tolvaptan improves kidney health in polycystic kidney disease

Tolvaptan improves kidney health in polycystic kidney disease

Study highlights potential treatment that reduces kidney growth

Study highlights potential treatment that reduces kidney growth

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.